DDrare: Database of Drug Development for Rare Diseases

26. HTLV-1関連脊髄症
［臨床試験数：26，薬物数：46（DrugBank：27），標的遺伝子数：37，標的パスウェイ数：123］

Searched query = "HTLV-1-associated myelopathy", "Tropical spastic paraparesis", "HTLV-1", "HTLV-I-associated myelopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Amniotic Epithelial Cells; Amniotic epithelial cells; Bortezomib; Ciclosporin; Costicosteroids; Cyclophosphamide; Doxorubicin; Doxorubicin Hydrochloride; Doxorubicin hydrochloride; Etoposide; Filgrastim; Hu MiK-Beta-1; Human interferon beta; Interferon alfa; Interferon beta; Interferon beta-1a; KW-0761; KW-0761 0.3 mg/kg IV; Lamivudine; Lenalidomide; Methylprednisolone; Mogamulizumab; NK Cells; NK cells; Nivolumab; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Pentosan polysulfate; Pentoxifylline; Prednisolone; Prednisone; Propantheline; Propantheline Bromide; Raltegravir; Raltegravir and Zidovudine; Recombinant human interferon beta-1a; Recombinant interferon alfa; Sulfate; Tamibarotene; Valproic acid; Valproid acid plus corticosteroids; Vincristine; Vincristine Sulfate; Vincristine sulfate; Zidovudine; Zidovudine/lamivudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04301076 (ClinicalTrials.gov)	June 15, 2020	6/3/2020	Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (EPOCH) for Adult T-Cell Leukemia-Lymphoma (ATL)	A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection	Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Prednisone;Drug: Vincristine Sulfate	National Cancer Institute (NCI)	NULL	Recruiting	18 Years	N/A	All	30	Phase 1	United States
2	NCT01000285 (ClinicalTrials.gov)	September 2010	19/10/2009	EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma	Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma	Leukemia-Lymphoma, Adult T-Cell	Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclophosphamide;Drug: Raltegravir	Washington University School of Medicine	NULL	Completed	18 Years	N/A	All	18	Phase 1;Phase 2	United States
3	NCT00041327 (ClinicalTrials.gov)	October 2002	8/7/2002	Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma	Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma	Lymphoma	Biological: filgrastim;Biological: recombinant interferon alfa;Drug: Etoposide;Drug: cyclophosphamide;Drug: doxorubicin hydrochloride;Drug: lamivudine;Drug: prednisone;Drug: vincristine sulfate;Drug: zidovudine	AIDS Malignancy Consortium	National Cancer Institute (NCI)	Completed	18 Years	120 Years	Both	19	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04301076
(ClinicalTrials.gov)

June 15, 2020

6/3/2020

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (EPOCH) for Adult T-Cell Leukemia-Lymphoma (ATL)

A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection

Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Prednisone;Drug: Vincristine Sulfate

National Cancer Institute (NCI)

NULL

Recruiting

18 Years

N/A

All

Phase 1

United States

NCT01000285
(ClinicalTrials.gov)

September 2010

19/10/2009

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma

Leukemia-Lymphoma, Adult T-Cell

Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclophosphamide;Drug: Raltegravir

Washington University School of Medicine

NULL

Completed

18 Years

N/A

All

Phase 1;Phase 2

United States

NCT00041327
(ClinicalTrials.gov)

October 2002

8/7/2002

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma

Lymphoma

Biological: filgrastim;Biological: recombinant interferon alfa;Drug: Etoposide;Drug: cyclophosphamide;Drug: doxorubicin hydrochloride;Drug: lamivudine;Drug: prednisone;Drug: vincristine sulfate;Drug: zidovudine

AIDS Malignancy Consortium

National Cancer Institute (NCI)

Completed

18 Years

120 Years

Both

Phase 2

United States